PRESS RELEASE published on 10/21/2024 at 20:00, 1 year 1 month ago Informations privilégiées / Autres communiqués ABIONYX Pharma reçoit un avis positif de l'EMA pour le CER-001 dans la Déficience en LCAT. L'EMA admissible à la soumission de deux lots prospectifs de validation du procédé de fabrication ABIONYX Pharma CER-001 EMA LCAT Validation Du Procédé
PRESS RELEASE published on 10/21/2024 at 20:00, 1 year 1 month ago Inside Information / Other news releases ABIONYX Pharma receives positive feedback from EMA for CER-001 in LCAT Deficiency, allowing submission of data from 2 prospective process validation batches for MAA manufacturing ABIONYX Pharma CER-001 EMA LCAT Deficiency Process Validation Batches
BRIEF published on 08/22/2024 at 18:05, 1 year 3 months ago ABIONYX Pharma : Bilan du 1er semestre 2024 Chiffre D'affaires Biotechnologie Trésorerie Levée De Fonds ABIONYX Pharma
BRIEF published on 08/22/2024 at 18:05, 1 year 3 months ago ABIONYX Pharma: Review of the first half of 2024 Biotechnology Fundraising Treasury Turnover ABIONYX Pharma
PRESS RELEASE published on 08/22/2024 at 18:00, 1 year 3 months ago Informations privilégiées / Autres communiqués ABIONYX Pharma publie sa position de trésorerie du 1er semestre 2024 avec un chiffre d’affaires consolidé de 2,4 M€. Levée de fonds de 3,4 M€ pour renforcer la trésorerie Chiffre D'affaires Biotechnologie Trésorerie Levée De Fonds ABIONYX Pharma
PRESS RELEASE published on 08/22/2024 at 18:00, 1 year 3 months ago Inside Information / Other news releases ABIONYX Pharma reports €2.4m sales and €5.3m cash position for H1 2024, focused on innovative therapies. Raised €3.4m for sepsis program in the US Sales Cash Position Innovative Therapies ABIONYX Pharma Sepsis
BRIEF published on 07/01/2024 at 09:27, 1 year 5 months ago ABIONYX Successfully Completes €3.4 Million Capital Increase Capital Increase Biotech Shares And Warrants ABIONYX Sepsis Development
BRIEF published on 07/01/2024 at 09:27, 1 year 5 months ago ABIONYX finalise avec succès une augmentation de capital de 3,4 millions d'euros Augmentation De Capital Actions Et Bons De Souscription Biotechnologies ABIONYX Développement De La Septicémie
PRESS RELEASE published on 07/01/2024 at 09:22, 1 year 5 months ago Inside Information / Other news releases ABIONYX successfully completes a capital increase of c.€3.4 million through the issuance of shares with warrants. The fundraising aims to strengthen the company's cash position for its development in sepsis and the United States Fundraising Capital Increase Sepsis ABIONYX Shares With Warrants
BRIEF published on 06/27/2024 at 19:27, 1 year 5 months ago ABIONYX Pharma Achieves Unanimous Approval at Combined General Meeting Shareholders Biotech General Meeting Resolutions ABIONYX Pharma
Published on 12/05/2025 at 15:35, 8 minutes ago XCF Global Moves to Double SAF Production with New Rise Reno Expansion
Published on 12/05/2025 at 15:00, 43 minutes ago Calidi Biotherapeutics and Nova Minerals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Published on 12/05/2025 at 14:00, 1 hour 43 minutes ago Ocean Power Technologies Attending the 3rd Annual DealFlow Discovery Conference
Published on 12/05/2025 at 14:00, 1 hour 43 minutes ago Bonk, Inc. Highlights Major Ecosystem Milestone: Launch of Regulated BONK ETP on SIX Swiss Exchange
Published on 12/05/2025 at 15:38, 4 minutes ago Form 8.3 - The Vanguard Group, Inc.: Unite Group plc, The
Published on 12/05/2025 at 15:36, 6 minutes ago Form 8.3 - The Vanguard Group, Inc.: Dowlais Group plc
Published on 12/05/2025 at 15:35, 7 minutes ago Form 8.3 - The Vanguard Group, Inc.: American Axle & Manufacturing Holdings, Inc.
Published on 12/05/2025 at 15:33, 9 minutes ago Form 8.3 - The Vanguard Group, Inc.: Qualcomm Incorporated
Published on 12/05/2025 at 15:32, 10 minutes ago Form 8.3 - The Vanguard Group, Inc.: Alphawave IP Group plc
Published on 12/05/2025 at 15:10, 32 minutes ago Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 15:10, 32 minutes ago Mersen : nombre d'actions et de droits de vote au 30 novembre 2025
Published on 12/05/2025 at 13:58, 1 hour 44 minutes ago RELATIF A LA MISE A DISPOSITION DU PUBLIC DE LA NOTE D'INFORMATION ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES, NOTAMMENT JURIDIQUES, FINANCIERES ET COMPTABLES DE LEGRAND FRANCE
Published on 12/05/2025 at 08:45, 6 hours 58 minutes ago Air Liquide va étendre et électrifier son unité de production d'oxygène à Shaanxi, soutenant ainsi l'engagement de la Chine à décarboner son industrie
Published on 12/05/2025 at 08:45, 6 hours 58 minutes ago Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
